Your browser doesn't support javascript.
loading
Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease.
Rosas, Irene; Martínez, Carmen; Clarimón, Jordi; Lleó, Alberto; Illán-Gala, Ignacio; Dols-Icardo, Oriol; Borroni, Barbara; Almeida, Maria Rosário; van der Zee, Julie; Van Broeckhoven, Christine; Bruni, Amalia C; Anfossi, Maria; Bernardi, Livia; Maletta, Raffaele; Serpente, María; Galimberti, Daniela; Scarpini, Elio; Rossi, Giacomina; Caroppo, Paola; Benussi, Luisa; Ghidoni, Roberta; Binetti, Giuliano; Nacmias, Benedetta; Sorbi, Sandro; Piaceri, Irene; Bagnoli, Silvia; Antonell, Anna; Sánchez-Valle, Raquel; De la Casa-Fages, Beatriz; Grandas, Francisco; Diez-Fairen, Mónica; Pastor, Pau; Ferrari, Raffaele; Álvarez, Victoria; Menéndez-González, Manuel.
Afiliação
  • Rosas I; Laboratorio de Genética, Hospital Universitario Central de Asturia, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias -ISPA, Oviedo, Spain.
  • Martínez C; Instituto de Investigación Sanitaria del Principado de Asturias -ISPA, Oviedo, Spain; Servicio de Neurología, Hospital Universitario de Cabueñes, Gijón, Spain.
  • Clarimón J; Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain; Center for Networker Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
  • Lleó A; Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain; Center for Networker Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
  • Illán-Gala I; Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain; Center for Networker Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
  • Dols-Icardo O; Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain; Center for Networker Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
  • Borroni B; Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Almeida MR; Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
  • van der Zee J; Neurodegenerative Brain Diseases Group, Center for Molecular Neurology, VIB, Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
  • Van Broeckhoven C; Neurodegenerative Brain Diseases Group, Center for Molecular Neurology, VIB, Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
  • Bruni AC; Regional Neurogenetic Centre, ASP CZ, Lamezia Terme, Catanzaro, Italy.
  • Anfossi M; Regional Neurogenetic Centre, ASP CZ, Lamezia Terme, Catanzaro, Italy.
  • Bernardi L; Regional Neurogenetic Centre, ASP CZ, Lamezia Terme, Catanzaro, Italy.
  • Maletta R; Regional Neurogenetic Centre, ASP CZ, Lamezia Terme, Catanzaro, Italy.
  • Serpente M; Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, University of Milan, Milan, Italy; Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Neurodegenerative Diseases Unit, Milan, Italy.
  • Galimberti D; Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, University of Milan, Milan, Italy; Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Neurodegenerative Diseases Unit, Milan, Italy.
  • Scarpini E; Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, University of Milan, Milan, Italy; Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Neurodegenerative Diseases Unit, Milan, Italy.
  • Rossi G; Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Caroppo P; Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Benussi L; Fatebenefratelli Biobank Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio- Fatebenefratelli, Brescia, Italy.
  • Ghidoni R; Fatebenefratelli Biobank Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio- Fatebenefratelli, Brescia, Italy.
  • Binetti G; Fatebenefratelli Biobank Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio- Fatebenefratelli, Brescia, Italy.
  • Nacmias B; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence Azienda Ospedaliero-Universitaria CareggiViale, Florence, Italy.
  • Sorbi S; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence Azienda Ospedaliero-Universitaria CareggiViale, Florence, Italy.
  • Piaceri I; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence Azienda Ospedaliero-Universitaria CareggiViale, Florence, Italy.
  • Bagnoli S; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence Azienda Ospedaliero-Universitaria CareggiViale, Florence, Italy.
  • Antonell A; Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Fundació Clínic per a la Recerca Biomèdica, Institut d'Investigacions Biomeèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Sánchez-Valle R; Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Fundació Clínic per a la Recerca Biomèdica, Institut d'Investigacions Biomeèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • De la Casa-Fages B; Movement Disorders Unit, Neurology Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain.
  • Grandas F; Movement Disorders Unit, Neurology Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain.
  • Diez-Fairen M; Movement Disorders Unit, Department of Neurology (P.P.), University Hospital Mutua de Terrassa, Terrasa, Barcelona, Spain; Fundació per la Recerca, Biomèdica i Social Mútua de Terrassa, Terrassa, Barcelona, Spain.
  • Pastor P; Movement Disorders Unit, Department of Neurology (P.P.), University Hospital Mutua de Terrassa, Terrasa, Barcelona, Spain; Fundació per la Recerca, Biomèdica i Social Mútua de Terrassa, Terrassa, Barcelona, Spain.
  • Ferrari R; Department of Neurodegenerative Disease, University College London, Institute of Neurology, Queen Square, London, UK.
  • Álvarez V; Laboratorio de Genética, Hospital Universitario Central de Asturia, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias -ISPA, Oviedo, Spain. Electronic address: victoria.alvarez@sespa.es.
  • Menéndez-González M; Instituto de Investigación Sanitaria del Principado de Asturias -ISPA, Oviedo, Spain; Servicio de Neurología, Hospital Universitario Central de Asturias, Oviedo, Spain.
Neurobiol Aging ; 87: 139.e1-139.e7, 2020 03.
Article em En | MEDLINE | ID: mdl-31810584
ABSTRACT
We analyzed the frequency of intermediate alleles (IAs) in the ATXN1, ATXN2, and HTT genes in several neurodegenerative diseases. The study included 1126 patients with Alzheimer's disease (AD), 440 patients with frontotemporal dementia (FTD), and 610 patients with Parkinson's disease. In all cohorts, we genotyped ATXN1 and ATXN2 CAG repeats. In addition, in the FTD cohort, we determined the number of HTT CAG repeats. The frequency of HTT IAs was higher in patients with FTD (6.9%) versus controls (2.9%) and in the C9orf72 expansion noncarriers (7.2%) versus controls (2.9%), although the difference was nonsignificant after correction for multiple testing. Compared with controls, progressive nonfluent aphasia (PNFA) groups showed a significantly higher frequency of HTT IAs (13.6% vs. 2.9% controls). For the ATXN2 gene, we observed an increase in IA frequency in AD cases (AD 4.1% vs. controls 1.8%) and in the behavioral FTD group (4.8% vs. 1.8%). For the ATXN1 gene, we found a significant increase of IAs in patients with PNFA (18.6%) versus controls (6.7%). In conclusion, our work suggests that the HTT and ATXN1 IAS may contribute to PNFA pathogenesis and point to a link between ATXN2 IAS and AD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Repetições de Trinucleotídeos / Demência Frontotemporal / Doença de Alzheimer / Ataxina-2 / Ataxina-1 / Proteína Huntingtina Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Repetições de Trinucleotídeos / Demência Frontotemporal / Doença de Alzheimer / Ataxina-2 / Ataxina-1 / Proteína Huntingtina Idioma: En Ano de publicação: 2020 Tipo de documento: Article